Scholarships and research projects public funding

  • On November 25, 1980, he was granted a “Team Research Aid” from the National Institute for Student Assistance and Promotion (Ministry of Education).
  • On June 14, 1983, he was awarded a scholarship for the “Training of Research Staff in Spain,” which he enjoyed during the 1983-84 academic year (Ministry of Education).
  • On June 2005, he was awarded a research grant from the Biomedical Research Foundation of the “Príncipe de Asturias” University Hospital, to carry out the research project; “Measurement of intracorneal pressure in the rabbit,” Project of which he is principal investigator, being collaborating researcher Ms. Gema Bolívar de Miguel. Aid FIB HUPA Nº 2005-3.
  • On November 2008, funding was granted by the Ministry of Science and Innovation, Carlos III Health Institute, FIS project file PI08 / 0602, call 2008, three years in duration, entitled; “Effects of Prostaglandin Treatment on Corneal Biomechanical Properties.” Principal investigator; Miguel A. Teus.
  • On June 2012, he was awarded a research grant from the Biomedical Research Foundation of the “Príncipe de Asturias” University Hospital, to carry out the research project; “Effect of treatment with timolol maleate on compressibility of the cornea in vivo. An animal study. ” Project of which Gema Bolivar is principal investigator, and collaborating researcher Miguel A. Teus. Help FIB PI 11-01.
  • On November 2012, financing was granted by the Ministry of Science and Innovation, Carlos III Health Institute, FIS project, file PI12 / 02637, 2012 call, three years in duration, total amount 44,165 Euros, titled; “Study of changes in corneal elasticity by treatment with latanoprost.” Principal investigator; Miguel A. Teus.

Scholarships and research projects privately financed

  • Participates, as Principal Investigator, in the conduct of the phase III clinical trial: «3 months evaluation of efficacy and safety of betaxolol 0.25% suspension / Pilocarpine HCL 1.75% combination with N-lauroyl sarcosine, compared to betaxolol 0.25 % suspension / pilocarpine HCL 1.75% combination without N-lauroyl sarcosine ». Protocol No. C-91-79, October 1995. Promotor, Alcon S.A.
  • Participates, as Principal Investigator, in carrying out the phase III clinical trial: «Clinical evaluation of the efficacy and safety of 0.5% levobunolol ophthalmic solution compared to Betagan 0.5%, ophthalmic solution, in the treatment of patients with primary open-angle glaucoma or ocular hypertension. ” Protocol No. C-95-100. September 1996. Promotor, Alcon S.A.
  • Participates, as Principal Investigator, in the conduct of the phase III clinical trial: «Multicenter, triple-blind study and adjuvant treatment, lasting 3 months, on the efficacy and safety of the 1% administered Brinzolamide ophthalmic suspension (AL-4862) administered Twice a day (BID) and 2% Dorzolamide ophthalmic solution (TRUSOPT) administered twice a day (BID) in the treatment of patients with primary open angle glaucoma or ocular hypertension in treatment with timolol. Protocol C-95-39, February 1997. Promotor, Alcon S.A.
  • Participates, as Coordinating Investigator for Spain, in the clinical trial: Comparative study of the reducing effect of intraocular pressure and the safety of Latanoprost 0.005% and dorzolamide 2% vs. timolol 0.5% and dorzolamide 2%, in patients with glaucoma of open angle or ocular hypertension. Phase IIIb, multicenter, parallel, randomized, double-blind study, November 1997. Promotor, Alcon S.A.
  • Participates, as Principal Investigator, in carrying out the clinical trial: Comparative study of the reducing effect of intraocular pressure and the safety of Latanoprost 0.005% and dorzolamide 2% vs. timolol 0.5% and dorzolamide 2%, in patients with glaucoma open angle or ocular hypertension. Phase IIIb, multicenter, parallel, randomized, double-blind study. January 1998. Promotor, Alcon S.A.
  • Participates, as Principal Investigator, in carrying out the phase III clinical trial: Nine-month triple-blind primary therapy study, with parallel groups, to evaluate the safety and efficacy of AL-6221 0.0015% and AL-6221 0.004% compared to timolol 0.5% in patients with open angle glaucoma or ocular hypertension. Protocol code C-97-79. June 1998. Promotor, Alcon S.A.
  • Participates, as Principal Investigator, in the conduct of the clinical trial: Two-year safety follow-up study of patients with changes in iris pigmentation, resulting from participation in phase III clinical trials of Travoprost (AL-6221) C- 97-71, C-97-72, C-97-73 and C-97-79 ″. Protocol code C-97-77. July 1999. Promotor, Alcon S.A.
  • Participates, as Principal Investigator, in the conduct of the phase III clinical trial: ”A 10-week study on the safety and efficacy of Travoprost ophthalmic solution (0.0015% and 0.004%) in patients with open angle glaucoma or hypertension ocular.” Protocol code C-00-04. July 2000. Promotor, Alcon S.A.
  • Participates, as Principal Investigator, in carrying out the phase III clinical trial; “A multicenter, double masked, randomized, two arm, parallel-group study of the efficacy and safety of 0.2% brimonidine tartrate / 0.5% timolol ophthalmic combination BID compared with concurrent administration of Timoftol 0.5% BID and Alphagan 0.2% IDB for 12 weeks in patients with glaucoma or ocular hypertension, with elevated IOP on monotherapy. ” Protocol code: 190342-507T-00. May 2001. Promotor, Allergan S.A.
  • Participates, as Principal Investigator, in carrying out the phase III clinical trial; “Comparative study of the efficacy and safety of the fixed combination of latanoprost and timolol (Xalacom) vs. Brimonidine and timolol in patients with elevated ocular hypertension. Multinational, randomized, masked study for the evaluator, in phase III of 6 months duration. ” Protocol code: 912-OPT-0076-021. June 2001. Promotor Pfizer S.A.
  • Participates, as Principal Investigator, in carrying out the phase III clinical trial; “A five year multicenter, open label study to evaluate the safetyof once daily instillation of Travoprost 0.004% eye drops (TRAVATAN) in subjects with open angle glaucoma or ocular hypertension.” Protocol code: C-02-20. July 2003. Alcon S.A.
  • Participates, as Principal Investigator, in carrying out the phase III clinical trial; “Multicenter, randomized, placebo-controlled, boble-masking study to evaluate the efficacy, safety, and tolerance of subconjunctival injections of 100micrograms of the human monoclonal antibody anti-TGFBeta2 CAT-152 as an agent to modulate wound healing after trabeculectomy.” Protocol code: CAT-152-0201. July 2003.
  • Promoter, Cambridge Antibody Technology, and Biomedical Research Center, National Institute of Health, UK.
  • Participates, as Principal Investigator, in the multicenter and international prospective study; “ESCRS study of prophylaxis of postoperative endophthalmitis after cataratact surgery”. Sponsored by the European Society of Cataract and Refractive Surgeons, (ESCRS). 2006.
  • Participates, as Principal Investigator, in the phase III clinical trial; “Multicenter, randomized, double-blind, six-week study to evaluate the efficacy and safety of the single morning administration of travoprost / timolol compared to twice daily administration of dorzolamide / timolol in patients with open-angle glaucoma or ocular hypertension ” Protocol code C-05-25. June 2006. Promotor, Alcon S.A.
  • Participates, as Principal Investigator, in the phase IV clinical trial; “Prospective eye safety cohort epidemiological study in patients treated with macugen injections for age-related macular degeneration (AMD) in Europe”. Study code; A5751019. July 2006. Promoter, Pfizer S.A.
  • Participates, as Principal Investigator and as coordinator for Spain, in the phase IV clinical trial; “IMCA Study,” Impact on quality “; Assessment of the degree of compliance with the recommendations for the treatment of glaucoma from the European Glaucoma Society guide, using the achievable benchmarks of care (ABC). Study sponsored by Pfizer S.A. June 2007.
  • Participate, as Principal Investigator of the phase III clinical trial; “Three-month, double-masked, multicenter study comparing the safety and efficacy of the travoprost / brinzolamide eye drops suspension vs. travatan vs. azopt combination in patients with open-angle glaucoma or ocular hypertension. Study code; C-07-63. November 2008. Promotor, Alcon S.A.
  • Participate, as Principal Investigator of the phase III clinical trial; “A Multicenter, Randomized, Double-Masked, Parallel-Group Study Evaluating the Efficacy and Safety of Cyclosporine Ophthalmic Solution 0.010% Compared with its Vehicle Administered QID for 3 Months Followed by a 9 Month Open-Label Phase in Patients with Atopic Keratoconjunctivitis”. Study code 192371-016-00. Study sponsored by Allergan Ltd. January 2010.
  • Participates, as principal investigator, in the phase III clinical trial; “Evaluation of the efficacy and safety of preservative-free eye drops T2345 against Xalatan in patients with ocular hypertension or glaucoma. Phase III, international, multicenter, randomized, investigator-blind study of two parallel groups, compared to the reference product in 360 evaluable patients treated for 3 months. ” Study Code LT2345-PIII-12/08. Study sponsored by THEA (France). April 2010.
  • Participates, as principal investigator, in the Non-EPA study; Epidemiological study to assess the degree of progression of glaucoma or ocular hypertension and the factors that influence it. ” Protocol code A6641055. Study sponsored by Pfizer Spain. July 2010.
  • Participates, as principal investigator, in the phase III clinical trial: “Efficacy and Safety of Brinzolamide 10 mg / mL / Brimonidine 2 mg / mL Eye Drops, Suspension Compared to Brinzolamide 10 mg / mL Eye Drops, Suspension plus Brimonidine 2 mg / mL Eye Drops, Solution in Patients with Open-Angle Glaucoma or Ocular Hypertension. ” Study Code C-10-041. Study sponsored by Alcon S.A. July 2011.
  • Participates, as a collaborating researcher, in the phase III clinical trial: “Clinical safety study to compare a topical solution of GAAP Ofteno (latanoprost 0.005%) versus Xalatan (latanoprost 0.005%) as a reference product, in patients diagnosed with primary open angle glaucoma and / or ocular hypertension. ” Study code LAT-SOP-01-2010. Study sponsored by Laboratorios Sophia, July 2011.
  • Participate as a collaborating researcher in the phase IV clinical trial; “Study postmarket multicentric evaluation of the Aquesys XEN implant in moderate primary open angle glaucoma.” Study financed by the company Aquesys, Aliso Viejo, California USA. June 2014.
  • Participates, as principal investigator, in the titled clinical trial; “FAST study: rapid evaluation of ocular surface alterations”. Study funded by Laboratoires Thea, Clermont-Ferrand, France. October 2015.
  • Obtains an aid for a research project (“unrestricted grant”) on the effect of different femtosecond lasers for flap carving in “Femtolasik” surgery on the refractive result of the procedure. Abbott-AMO, Santa Ana, Calif. USES. October 2015.
  • Obtains an aid for a research project (“unrestricted grant”) on the effect of Femtolasik performed with a femtosecond laser of the “Intralase” type on the thickness of the layer of retinal nerve fibers. Abbott-AMO, Santa Ana, Calif. USES. March 2016.
  • Obtains a grant for a research project (“unrestricted grant”) on the development of a pig’s eye model to measure the homogeneity of the lasik flap stromal bed performed with a femtosecond laser. Abbott-AMO, Santa Ana, Calif. USES. March 2016.
  • Participates, as principal investigator, in the clinical trial entitled “A Phase II, Multicenter, Randomized, Double-Masked, 4 ParallelArms, Controlled 6-Month Trial Designed to Evaluate the Safety and Efficacy of PAD Ciclosporin (CsA 0.06% and 0.03%) Ophthalmic Dispersion Administered Once Daily in Combination with Lubricant Therapy and a 3-Month Post-Treatment Safety Follow-Up in Moderate to Severe Dry Eye Patients ”, study funded by MC2 Biotek, Compenhagen. March 2016.
  • Participates, as principal investigator, in the titled clinical trial; “Clinical research on the size of the corneal incision after IOL implantation with preloaded injector devices and a manual injector device.” Protocol code “ILN296-P001”, study sponsored by Alcon S.A. September 2016.
  • Participate, as a collaborating researcher, in the titled clinical trial; “Safety and Efficacy with Twice Daily Brinzolamide 1% / Brimonidine 0.2% (SIMBRINZA) as an Adjunctive Therapy to Travoprost 0.004% / Timolol 0.5% (DUOTRAV).” Protocol code GLJ576-P001, study sponsored by Alcon S.A. September 2016.
  • Participates, as principal investigator, in the phase II clinical trial entitled; “HELIX, SYL1001 double-blind clinical trial in patients with moderate to severe dry eye (DED).” Protocol code SYL1001_IV, No. EudraCT: 2016-003903-79, study sponsored by Sylentis SAU, July 2017.
  • Participates, as principal investigator, in the phase IV clinical trial entitled; “Post-marketing study of the Clareon® intraocular lens.” Protocol code ILJ-466 P003, study sponsored by Alcon S.A. March 2018.
  • Participates, as principal investigator, in the phase IV clinical trial entitled; “Long-term follow-up study of the XEN implant.” Protocol code EC / CMO-MA-EYE-0590/19. study sponsored by Allergan SA. June 2019.